Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. The company had revenue of $7.55 million for the quarter, compared to analysts' expectations of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%.
Sangamo Therapeutics Stock Performance
Shares of NASDAQ:SGMO traded up $0.02 during trading on Friday, reaching $0.86. The stock had a trading volume of 1,909,052 shares, compared to its average volume of 7,675,412. The business has a fifty day moving average price of $1.07 and a 200-day moving average price of $1.40. The stock has a market cap of $179.02 million, a PE ratio of -1.14 and a beta of 1.49. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Wells Fargo & Company reduced their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 31st. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday. Truist Financial cut their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Jefferies Financial Group cut their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, December 31st. Finally, StockNews.com cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $5.17.
Read Our Latest Stock Report on SGMO
About Sangamo Therapeutics
(
Get Free Report)
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Featured Stories
Before you consider Sangamo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.
While Sangamo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
